Skip to main content

Animations

MJFF Publications

6781 - 6790 of 8808 Results
Title
Year
  • Year
  • 2021
  • 2022
  • 2020
  • 2023
  • 2016
  • 2023
  • 2023
  • 2023
  • 2024
  • 2020
  • Summary Details
    OPEN
    Title: Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-021-00246-3
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-022-00375-3
    Citation Count: 26
  • Summary Details
    OPEN
    Title: BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-020-00965-9
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-023-01440-x
    Citation Count: 22
  • Summary Details
    OPEN
    Title: Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2016.2245
    Citation Count: 213
  • Summary Details
    OPEN
    Title: Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's
    Journal Name: European Journal of Neuroscience
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1111/ejn.16180
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2023.106343
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Interaction of an α-synuclein epitope with HLA-DRB1∗15:01 triggers enteric features in mice reminiscent of prodromal Parkinson’s disease
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuron.2023.07.015
    Citation Count: 32
  • Summary Details
    OPEN
    Title: Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease
    Journal Name: Aging and disease
    Publisher: Aging and Disease
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.14336/ad.2024.0323
    Citation Count: 0
  • Summary Details
    OPEN
    Title: GBA variants in REM sleep behavior disorder
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000010042
    Citation Count: 66
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.